recent publications

• academic article

  • Palaninathan, S. K., Mohamedmohaideen, N. N., Snee, W. C., Kelly, J. W., Sacchettini, J. C. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer Journal of Molecular Biology  2008 382:1157-1167  DOI:10.1016/j.jmb.2008.07.029  PMID:18662699
  • Johnson, S. M., Petrassi, H. M., Palaninathan, S. K., Mohamedmohaideen, N. N., Purkey, H. E., Nichols, C., Chiang, K. P., Walkup, T., Sacchettini, J. C., Sharpless, K. B., Kelly, J. W. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation Journal of Medicinal Chemistry  2005 48:1576-1587  DOI:10.1021/jm049274d  PMID:15743199
  • Purkey, H. E., Palaninathan, S. K., Kent, K. C., Smith, C., Safe, S. H., Sacchettini, J. C., Kelly, J. W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity Chemistry & Biology  2004 11:1719-1728  DOI:10.1016/j.chembiol.2004.10.009  PMID:15610856
  • Adamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C., Kelly, J. W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis Journal of Medicinal Chemistry  2004 47:355-374  DOI:10.1021/jm030347n  PMID:14711308
  • Green, N. S., Palaninathan, S. K., Sacchettini, J. C., Kelly, J. W. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization Journal of the American Chemical Society  2003 125:13404-13414  DOI:10.1021/ja030294z  PMID:14583036
  • Razavi, H., Palaninathan, S. K., Powers, E. T., Wiseman, R. L., Purkey, H. E., Mohamedmohaideen, N. N., Deechongkit, S., Chiang, K. P., Dendle, M. T. A., Sacchettini, J. C., Kelly, J. W. Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action Angewandte Chemie-International Edition  2003 42:2758-2761  DOI:10.1002/anie.200351179  PMID:12820260
  • Sacchettini, J. C., Kelly, J. W. Therapeutic strategies for human amyloid diseases Nature Reviews Drug Discovery  2002 1:267-275  DOI:10.1038/nrd769  PMID:12120278
  • Jiang, X., Smith, C. S., Petrassi, H. M., Hammarstrom, P., White, J. T., Sacchettini, J. C., Kelly, J. W. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured Biochemistry  2001 40:11442-11452  DOI:10.1021/bi011194d  PMID:11560492
  • Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., Kelly, J. W., Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors Nature Structural Biology  2000 7:312-321  DOI:10.1038/74082  PMID:10742177
  • Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., Kelly, J. W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation Proceedings of the National Academy of Sciences of the United States of America  1998 95:12956-12960  DOI:10.1073/pnas.95.22.12956  PMID:9789022